van der Sar, I. G.
Wijbenga, N.
Nakshbandi, G.
Aerts, J. G. J. V.
Manintveld, O. C.
Wijsenbeek, M. S.
Hellemons, M. E.
Moor, C. C. http://orcid.org/0000-0002-5295-2877
Article History
Received: 1 June 2021
Accepted: 26 August 2021
First Online: 17 September 2021
Declarations
:
: Not applicable.
: Not applicable.
: Drs. Van der Sar reports grants from Boehringer Ingelheim, during the conduct of the study. Drs. Wijbenga has nothing to disclose. Drs. Nakshbandi has nothing to disclose. Dr. Aerts reports personal fees and non-financial support from MSD; personal fees from BMS, Boehringer Ingelheim, Amphera, Eli Lilly, Takeda, Bayer, Roche, Astra Zeneca outside the submitted work. In addition, Dr. Aerts has a patent on allogenic tumor cell lysate licensed to Amphera, a patent combination immunotherapy in cancer pending, and a patent biomarker for immunotherapy pending. Dr. Manintveld has nothing to disclose. Dr. Wijsenbeek reports grants and other from Boehringen Ingelheim and Hoffman la Roche, and other from Galapagos, Novartis, Respivant, Savara outside the submitted work. All grants and fees were paid to dr Wijsenbeek’s institution. Dr. Hellemons has nothing to disclose. Dr. Moor reports grants and other from Boehringer-Ingelheim outside the submitted work.